TAIHO PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 1963-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.taiho.co.jp
A Study of TAS3731 in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy Adult Males
- Interventions
- Drug: TAS3731 Dose1Drug: TAS3731 Dose2Drug: TAS3731 Dose3Drug: Placebo
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 238
- Registration Number
- NCT05691660
- Locations
- 🇯🇵
A site selected by Taiho Pharmaceutical Co., Ltd., Tokyo, Japan
A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects
Phase 1
Completed
- Conditions
- Healthy Male Subjects
- Interventions
- Drug: TAS-303, [14C]TAS-303
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05621447
- Locations
- 🇯🇵
A site selected by Taiho Pharmaceutical Co., Ltd., Tokyo, Japan
A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria
Phase 2
Completed
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Drug: TAS5315 Dose 2Drug: PlaceboDrug: TAS5315 Dose 1Drug: TAS5315 Dose 3Drug: TAS5315 Dose 4Drug: TAS5315 Dose 5
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT05335499
- Locations
- 🇯🇵
A site selected by Taiho Pharmaceutical Co., Ltd., Yokohama, Japan
A Study of Pimitespib in Combination with Imatinib in Patients with GIST (CHAPTER-GIST-101)
Phase 1
Recruiting
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT05245968
- Locations
- 🇦🇺
Flinders Medical Center, Adelaide, Australia
🇦🇺Alfred Health, Melbourne, Australia
🇨🇳Beijing Cancer Hospital, Beijing, China
AB122 Platform Study
Phase 1
Recruiting
- Conditions
- Advanced or Metastatic Solid TumorPancreatic Ductal AdenocarcinomaColorectal CancerNon-small Cell Lung CancerGastric CancerAlveolar Soft Part SarcomaEsophageal CancerHead and Neck CancerBiliary Tract Cancer
- Interventions
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 715
- Registration Number
- NCT04999761
- Locations
- 🇯🇵
A site selected by Taiho Pharmaceutical Co., Ltd., Wakayama, Japan
Mass Balance Study of [14C] TAS-205 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Male Subjects
- Interventions
- Drug: TAS-205, [14C]TAS-205
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT04825431
- Locations
- 🇯🇵
A site selected by Taiho Pharmaceutical Co., Ltd., Tokyo, Japan
Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
Phase 1
Recruiting
- Conditions
- RET-altered Non Small Cell Lung CancerRET-altered Solid Tumors
- Interventions
- Drug: TAS0953/HM06
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 244
- Registration Number
- NCT04683250
- Locations
- 🇯🇵
Kansai Medical University Hospital, Hirakata-shi, Osaka, Japan
🇯🇵Tohoku University Hospital, Sendai-shi, Miyagi, Japan
🇯🇵Okayama University Hospital, Okayama-shi, Okayama, Japan
A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD）
Phase 3
Active, not recruiting
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Drug: TAS-205 [Ambulatory Cohort] [Non-ambulatory Cohort]Drug: Placebo [Ambulatory Cohort] only
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT04587908
- Locations
- 🇯🇵
A site selected by Taiho Pharmaceutical Co., Ltd., Tokyo, Japan
A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence
Phase 2
Completed
- Conditions
- Stress Urinary Incontinence
- Interventions
- Drug: TAS-303 18 mg/dayDrug: Placebo
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 231
- Registration Number
- NCT04512053
- Locations
- 🇯🇵
A site selected by Taiho Pharmaceutical Co., Ltd., Tokyo, Japan
Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: PlacebosDrug: TAS5315 low doseDrug: TAS5315 high dose
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2020-08-17
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 91
- Registration Number
- NCT03605251
- Locations
- 🇯🇵
Taiho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
© Copyright 2025. All Rights Reserved by MedPath